Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of the cytoskeletal protein dystrophin. Constitutive utrophin expression, a structural and functional paralogue of dystrophin, can successfully prevent the dystrophic pathology in the dystrophin-deficient m...
Main Authors: | Guiraud, S, Edwards, B, Squire, S, Moir, L, Berg, A, Babbs, A, Ramadan, N, Wood, M, Davies, K |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2018
|
Similar Items
-
Identification of serum protein biomarkers for utrophin based DMD therapy.
by: Guiraud, S, et al.
Published: (2017) -
Second-generation compound for the modulation of utrophin in the therapy of DMD
by: Guiraud, S, et al.
Published: (2015) -
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019) -
Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
by: Kennedy, T, et al.
Published: (2017) -
Utrophin upregulation in DMD therapy: current status and new tools for the future
by: Fairclough, R, et al.
Published: (2011)